4.7 Article

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 207, Issue 10, Pages 2187-2194

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20100643

Keywords

-

Funding

  1. National Institutes of Health [AI73748, NS038037, NS045937, NS030843, NS054096, CA72669, HL56067, AI056299]
  2. National Multiple Sclerosis Society
  3. Juvenile Diabetes Research Foundation Center for Immunological Tolerance at Harvard
  4. European Molecular Biology Organization
  5. Ragon Institute of the Massachusetts Institute of Technology
  6. Massachussetts General Hospital and Harvard
  7. Sankyo Foundation of Life Science

Ask authors/readers for more resources

The immune response plays an important role in staving off cancer; however, mechanisms of immunosuppression hinder productive anti-tumor immunity. T cell dysfunction or exhaustion in tumor-bearing hosts is one such mechanism. PD-1 has been identified as a marker of exhausted T cells in chronic disease states, and blockade of PD-1-PD-1L interactions has been shown to partially restore T cell function. We have found that T cell immunoglobulin mucin (Tim) 3 is expressed on CD8(+) tumor-infiltrating lymphocytes (TILs) in mice bearing solid tumors. All Tim-3(+) TILs coexpress PD-1, and Tim-3(+)PD-1(+) TILs represent the predominant fraction of T cells infiltrating tumors. Tim-3(+)PD-1(+) TILs exhibit the most severe exhausted phenotype as defined by failure to proliferate and produce IL-2, TNF, and IFN-gamma. We further find that combined targeting of the Tim-3 and PD-1 pathways is more effective in controlling tumor growth than targeting either pathway alone.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available